Nuclera has established a network of distribution partnerships across Asia-Pacific and the Middle East, expanding access to its eProtein Discovery system in response to rising global demand for faster, scalable protein expression tools.

The company has secured agreements with distributors in China, Japan, South Korea, Singapore, Taiwan, and Israel to support local customers and strengthen its commercial presence in key international markets. Partners include MineBio Life Sciences (China), Kiko Tech (Japan), CHAYON Laboratories (South Korea), Sciencewerke (Singapore), Cold Spring Biotech (Taiwan), and Yair Or Technologies (Israel).

Nuclera, headquartered in Cambridge, UK and Boston, USA, said the move marks a major milestone in its commercial growth strategy and will provide localized technical support as adoption of its benchtop eProtein Discovery system increases.

The company recently expanded the system’s capabilities to include both membrane and soluble protein expression, which it says is a crucial step in supporting drug discovery efforts targeting proteins – which make up the majority of therapeutic targets.

Protein expression remains a bottleneck in early-stage drug development, particularly for challenging targets. Nuclera’s system aims to reduce time and complexity in both cell-based and cell-free expression workflows, helping researchers produce high-quality, functional proteins at scale.

Michael Chen, co-founder and CEO at Nuclera, said the new partnerships reflect growing international interest in the technology.

“Our expansion into APAC and the Middle East is driven by increased global demand and underscores the impact of eProtein Discovery in transforming how proteins are made,” he said. “We’ve already seen installations in leading pharmaceutical and academic institutions, and now in our first CRO customer, marking an exciting step forward in broader adoption.”

Chief commercial officer Joseph Bertelsen added that the new partnerships are critical to scaling operations globally: “These distribution agreements come at a pivotal time as we accelerate commercial rollout following our recent Series C funding round. Each partner brings deep local knowledge and technical expertise to support customers working on complex protein-based research.”

The company said it will continue to focus on expanding access to its platform and supporting translational research and drug discovery programmes globally.